Emtriva (Emtricitabine, FTC)

See also: Drug Interactions | Medication Side Effects | All HIV Medications

Brand Name:	Emtriva
Generic Name:	Emtricitabine, FTC
Adult Single Dose:	One 200-mg capsule or 240-mg (24 ml) oral solution (once a day)
Food & Liquid Restrictions:	None
Drug Class:	NRTI

The Basics

An Overview of Emtriva (Emtricitabine) (September 21, 2012)
From AIDSinfo
Emtricitabine (Emtriva) (August 20, 2012)
To read PDF, click here.
From AIDS InfoNet
Emtriva (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Patient Information About Emtriva (Emtricitabine, FTC) (PDF) (November 2011)
From Gilead Sciences, Inc.
Emtriva (Emtricitabine, FTC) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
FTC (Emtricitabine, Emtriva) (August 15, 2006)
From AIDS Treatment Data Network
Emtriva (Emtricitabine) (November 2005)
To read PDF, click here.
From The Center for AIDS
Labeling Changes for Emtriva (September 28, 2005)
Specific modifications since the label was last updated are highlighted.
From U.S. Food and Drug Administration
Three New Drugs Approved by FDA (November/December 2003)
An overview of Fuzeon (enfuvirtide, T-20), Reyataz (atazanavir) and Emtriva (emtricitabine, FTC).
In Survival News, from AIDS Survival Project
The Bottom Line on T-20 (Fuzeon), Atazanavir (Reyataz) and FTC (Emtriva) (October 2003)
Bare-bones highlights of three of this year's new HIV medications.
To read PDF, click here.
In Project Inform Perspective, from Project Inform

VIEW ALL ARTICLES

News & Research

Clinical Trials Using Emtricitabine (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health
Switching to Rilpivirine/Tenofovir/FTC Fixed-Dose Combination From Boosted-PI Regimen: SPIRIT Study Draws the Line at 24 Weeks (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
Gilead and Tibotec Agree on New Single-Tablet Regimen (November 23, 2011)
In Positively Aware, from Test Positive Aware Network
Gilead and J&J Expand HIV Cocktail Partnership (November 16, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Gilead Raises Prices of HIV Drugs, AHF Speaks Out Against Price Hike (April 4, 2011)
In Bloomberg Businessweek
Emtricitabine and Lamivudine May Be Similar, but Their Resistance Profiles Differ in Important Ways (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
Emtriva: New Pediatric Formulation and Labeling Changes (September 28, 2005)
From U.S. Food and Drug Administration
Gilead, Royalty Pharma to Pay Emory University $525 Million for Rights to Emtricitabine (July 19, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
No Difference Seen in Resistance Profiles of Emtricitabine and Lamivudine (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration

VIEW ALL ARTICLES